BACKGROUND AND OBJECTIVES: Published studies suggest that longer hemodialysis (HD) sessions are associated with improved morbidity and mortality, but few centers offer long sessions. The Western Infirmary renal unit has offered long overnight hemodialysis (LOH) (6 to 7 h) thrice weekly since 1998. The aim of this study was to describe patients who chose LOH and compare outcomes with patients on conventional hours (4 to 5 h) HD. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS: Patients who ever had LOH for three or more consecutive sessions were identified (n = 146). Indices of urea reduction ratio (URR), anemia, hyperphosphatemia, and predialysis BP (BP) control in a subgroup of all patients on LOH for at least 1 yr since 2004 were compared with age, sex, and diabetes-matched controls undergoing conventional duration HD. RESULTS: The mean age at the time of starting LOH was 51.8 yr and 74.7% started with a functioning arteriovenous fistula. Median duration of continuous LOH was 1.6 yr. Of those no longer on LOH, only 33.3% reverted to conventional hours HD (mean duration LOH 2.2 yr). When comparing LOH and conventional HD cohorts, there was increased URR and mean hemoglobin with a trend toward lower mean erythropoietin index. There was a trend toward fewer phosphate binder tablets but no difference in mean serum phosphate, BP, or number of prescribed antihypertensive medicines. CONCLUSIONS: LOH is a well tolerated hemodialysis option, associated with improved URR and better control of anemia.
BACKGROUND AND OBJECTIVES: Published studies suggest that longer hemodialysis (HD) sessions are associated with improved morbidity and mortality, but few centers offer long sessions. The Western Infirmary renal unit has offered long overnight hemodialysis (LOH) (6 to 7 h) thrice weekly since 1998. The aim of this study was to describe patients who chose LOH and compare outcomes with patients on conventional hours (4 to 5 h) HD. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS: Patients who ever had LOH for three or more consecutive sessions were identified (n = 146). Indices of urea reduction ratio (URR), anemia, hyperphosphatemia, and predialysis BP (BP) control in a subgroup of all patients on LOH for at least 1 yr since 2004 were compared with age, sex, and diabetes-matched controls undergoing conventional duration HD. RESULTS: The mean age at the time of starting LOH was 51.8 yr and 74.7% started with a functioning arteriovenous fistula. Median duration of continuous LOH was 1.6 yr. Of those no longer on LOH, only 33.3% reverted to conventional hours HD (mean duration LOH 2.2 yr). When comparing LOH and conventional HD cohorts, there was increased URR and mean hemoglobin with a trend toward lower mean erythropoietin index. There was a trend toward fewer phosphate binder tablets but no difference in mean serum phosphate, BP, or number of prescribed antihypertensive medicines. CONCLUSIONS:LOH is a well tolerated hemodialysis option, associated with improved URR and better control of anemia.
Authors: Robert M Lindsay; Fayez Alhejaili; Gihad Nesrallah; Rosemary Leitch; Laurie Clement; A Paul Heidenheim; Claude Kortas Journal: Am J Kidney Dis Date: 2003-07 Impact factor: 8.860
Authors: Eduardo Lacson; Jianglin Xu; Rita S Suri; Gihad Nesrallah; Robert Lindsay; Amit X Garg; Keith Lester; Norma Ofsthun; Michael Lazarus; Raymond M Hakim Journal: J Am Soc Nephrol Date: 2012-02-23 Impact factor: 10.121
Authors: Victor Gura; Matthew B Rivara; Scott Bieber; Raj Munshi; Nancy Colobong Smith; Lori Linke; John Kundzins; Masoud Beizai; Carlos Ezon; Larry Kessler; Jonathan Himmelfarb Journal: JCI Insight Date: 2016-06-02
Authors: Gihad E Nesrallah; Robert M Lindsay; Meaghan S Cuerden; Amit X Garg; Friedrich Port; Peter C Austin; Louise M Moist; Andreas Pierratos; Christopher T Chan; Deborah Zimmerman; Robert S Lockridge; Cécile Couchoud; Charles Chazot; Norma Ofsthun; Adeera Levin; Michael Copland; Mark Courtney; Andrew Steele; Philip A McFarlane; Denis F Geary; Robert P Pauly; Paul Komenda; Rita S Suri Journal: J Am Soc Nephrol Date: 2012-02-23 Impact factor: 10.121
Authors: Matthew B Rivara; Scott V Adams; Sooraj Kuttykrishnan; Kamyar Kalantar-Zadeh; Onyebuchi A Arah; Alfred K Cheung; Ronit Katz; Miklos Z Molnar; Vanessa Ravel; Melissa Soohoo; Elani Streja; Jonathan Himmelfarb; Rajnish Mehrotra Journal: Kidney Int Date: 2016-08-20 Impact factor: 10.612
Authors: Jonathan P Law; Luke Pickup; Davor Pavlovic; Jonathan N Townend; Charles J Ferro Journal: J Hum Hypertens Date: 2022-09-22 Impact factor: 2.877
Authors: Eduardo Lacson; Weiling Wang; Keith Lester; Norma Ofsthun; J Michael Lazarus; Raymond M Hakim Journal: Clin J Am Soc Nephrol Date: 2009-12-03 Impact factor: 8.237
Authors: Ron Wald; Andrew T Yan; Jeffrey Perl; Depeng Jiang; M Sandra Donnelly; Howard Leong-Poi; Philip A McFarlane; Jordan J Weinstein; Marc B Goldstein Journal: BMC Nephrol Date: 2012-01-19 Impact factor: 2.388